Mersana Therapeutics Inc Cash Flow-to-Debt Ratio
Mersana Therapeutics Inc cash flow-to-debt ratio. Mersana Therapeutics Inc (MRSN) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-3.19 Million could theoretically repay 0% of its total liabilities ($122.22 Million) in one year. Check cash flow quality index of Mersana Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mersana Therapeutics Inc (2015–2024)
Cash flow-to-debt ratio of Mersana Therapeutics Inc from 2015 to 2024. Historical debt coverage capacity for Mersana Therapeutics Inc across 10 annual periods. Check Mersana Therapeutics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Mersana Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
Mersana Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Mersana Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Mersana Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.53x | $-82.34 Million | $154.17 Million | ▲ +40.2% |
| 2023 | -0.89x | $-168.88 Million | $189.16 Million | ▼ -338.2% |
| 2022 | -0.20x | $-49.36 Million | $242.28 Million | ▲ +87.7% |
| 2021 | -1.66x | $-139.99 Million | $84.37 Million | ▼ -0.7% |
| 2020 | -1.65x | $-74.70 Million | $45.31 Million | ▲ +28.9% |
| 2019 | -2.32x | $-67.74 Million | $29.22 Million | ▼ -192.7% |
| 2018 | -0.79x | $-55.22 Million | $69.71 Million | ▼ -12.7% |
| 2017 | -0.70x | $-42.68 Million | $60.72 Million | ▼ -457.6% |
| 2016 | 0.20x | $31.59 Million | $160.71 Million | ▲ +216.5% |
| 2015 | -0.17x | $-9.64 Million | $57.10 Million | — |